Add to ORKG2 The triple negative breast cancer (TNBC) subtype represents a cancer that is highly aggressive with poor patient outcome. Current preclinical success has been gained through synthetic lethality, targeting genome instability with poly-ADP-ribose-polymerase (PARP) inhibition in breast cancer cells which harbour silencing of the homologous recombination (HR) pathway
Opinion statementInhibitors of poly (ADP-ribose) polymerase (PARP) have emerged as a new class of an...
Inhibitors of poly(ADP-ribose) (PAR) polymerase (PARPi) have recently entered the clinic for the tre...
Inhibitors of poly(ADP-ribose) (PAR) polymerase (PARPi) have recently entered the clinic for the tre...
Triple-negative breast cancer is a combative cancer type with a highly inflated histological grade t...
The triple-negative breast cancer (TNBC) subtype represents a cancer that is highly aggressive with ...
Triple-negative breast cancer (TNBC) is defined as a targets, i.e. ER or HER2, have been obstacles t...
Abstract In a pilot study, we evaluated the feasibility of real-time deep analysis of serial tumor s...
In contrast to endocrine-sensitive and HER2-positive breast cancer, novel agents capable of treating...
In contrast to endocrine-sensitive and HER2-positive breast cancer, novel agents capable of treating...
Since the proof of concept of synthetic lethality between poly(ADP-ribose) polymerase inhibition and...
Triple negative breast cancer (TNBC) remains as an aggressive form of cancer and represents 10-15% o...
Triple-negative breast cancer (TNBC) accounts for 15% to 20% of breast cancers. It is a heterogeneou...
Opinion statementInhibitors of poly (ADP-ribose) polymerase (PARP) have emerged as a new class of an...
Inhibitors of poly(ADP-ribose) (PAR) polymerase (PARPi) have recently entered the clinic for the tre...
Inhibitors of poly(ADP-ribose) (PAR) polymerase (PARPi) have recently entered the clinic for the tre...
Opinion statementInhibitors of poly (ADP-ribose) polymerase (PARP) have emerged as a new class of an...
Inhibitors of poly(ADP-ribose) (PAR) polymerase (PARPi) have recently entered the clinic for the tre...
Inhibitors of poly(ADP-ribose) (PAR) polymerase (PARPi) have recently entered the clinic for the tre...
Triple-negative breast cancer is a combative cancer type with a highly inflated histological grade t...
The triple-negative breast cancer (TNBC) subtype represents a cancer that is highly aggressive with ...
Triple-negative breast cancer (TNBC) is defined as a targets, i.e. ER or HER2, have been obstacles t...
Abstract In a pilot study, we evaluated the feasibility of real-time deep analysis of serial tumor s...
In contrast to endocrine-sensitive and HER2-positive breast cancer, novel agents capable of treating...
In contrast to endocrine-sensitive and HER2-positive breast cancer, novel agents capable of treating...
Since the proof of concept of synthetic lethality between poly(ADP-ribose) polymerase inhibition and...
Triple negative breast cancer (TNBC) remains as an aggressive form of cancer and represents 10-15% o...
Triple-negative breast cancer (TNBC) accounts for 15% to 20% of breast cancers. It is a heterogeneou...
Opinion statementInhibitors of poly (ADP-ribose) polymerase (PARP) have emerged as a new class of an...
Inhibitors of poly(ADP-ribose) (PAR) polymerase (PARPi) have recently entered the clinic for the tre...
Inhibitors of poly(ADP-ribose) (PAR) polymerase (PARPi) have recently entered the clinic for the tre...
Opinion statementInhibitors of poly (ADP-ribose) polymerase (PARP) have emerged as a new class of an...
Inhibitors of poly(ADP-ribose) (PAR) polymerase (PARPi) have recently entered the clinic for the tre...
Inhibitors of poly(ADP-ribose) (PAR) polymerase (PARPi) have recently entered the clinic for the tre...